Fibrinogen Levels and Cardiovascular Outcomes After PCI: What a Large Chinese Study Reveals
Percutaneous coronary intervention (PCI)—the procedure that opens blocked heart arteries with stents—is a cornerstone of care for coronary artery disease (CAD). But for doctors, predicting which patients will have long-term issues after PCI remains tricky. One unresolved question: Does fibrinogen—a blood protein key to clotting and inflammation—act as a causal risk factor for bad outcomes, or is it just a marker of other underlying health problems?
To answer this, researchers from Fuwai Hospital (National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences) analyzed data from 6293 patients who underwent PCI in 2013. Over two years of follow-up, they tracked how fibrinogen levels related to all-cause mortality—the most serious outcome—and whether fibrinogen added value to traditional risk assessments. Their findings, published in the Chinese Medical Journal in 2019, offer clarity for patients and clinicians alike.
What the Study Did
The team measured baseline fibrinogen (before PCI) using a standard lab test (modified Clauss method). They split patients into three groups based on fibrinogen levels:
- Low: <2.98 g/L
- Medium: 2.98–3.58 g/L
- High: ≥3.58 g/L
The main goal was to see if higher fibrinogen correlated with 2-year all-cause mortality. They also tested whether adding fibrinogen to a “basic model” of traditional risk factors (age, sex, diabetes, heart function, kidney function, LDL cholesterol) improved prediction.
Key Findings
- Higher fibrinogen = higher mortality: Patients in the high-fibrinogen group had a 1.7% 2-year mortality rate—nearly double the 0.9% rate in the low group and 1.0% in the medium group. This difference was statistically significant (log-rank test, P=0.022).
- Independent but not “added value”: Even after adjusting for traditional risk factors, high fibrinogen remained linked to a 34% higher risk of death (hazard ratio 1.339, P=0.005). But here’s the critical point: Adding fibrinogen to the basic model barely improved prediction. The area under the curve (AUC)—a measure of how well a model predicts outcomes—rose from 0.776 to just 0.787. This tiny change wasn’t statistically meaningful (P=0.889).
- Traditional risks still rule: Age, diabetes, left ventricular ejection fraction (LVEF, a measure of heart strength), kidney function, and LDL cholesterol were far stronger predictors of mortality than fibrinogen.
What It Means for Patients and Doctors
Fibrinogen is associated with worse outcomes after PCI—but it doesn’t tell doctors anything they don’t already learn from checking basic risk factors. This aligns with earlier research, like the AtheroGene study, which found fibrinogen predicts risk in stable CAD but doesn’t outperform traditional markers.
Why? Fibrinogen is an acute-phase reactant—it rises during inflammation, which plays a role in plaque rupture and blood clots (the main causes of heart attacks and stent problems). But fibrinogen is also tied to other risk factors: older age, smoking, obesity, and diabetes. These conditions explain most of the variation in fibrinogen levels—and most of the risk of death after PCI.
In short: Fibrinogen is a biomarker (a “red flag” for poor prognosis) but not a superior predictor to the risks doctors already track.
Limitations to Consider
The study has important caveats:
- Baseline only: Fibrinogen levels can change over time (e.g., during inflammation or treatment), but the team only measured them once.
- Single center: Data came from one top hospital in China, so results may not apply to diverse populations or smaller clinics.
- PCI-only: The study focused on patients who got stents—findings might not extend to people with CAD who don’t undergo PCI.
Conclusion
For patients, the takeaway is simple: Managing traditional risk factors (quitting smoking, controlling diabetes, taking statins) remains the best way to improve long-term outcomes after PCI. For doctors, fibrinogen can be a useful additional marker—but it won’t replace the basics.
As the researchers note: “Fibrinogen is associated with 2-year all-cause mortality in patients receiving PCI, but provides no additional information over a model including traditional risk factors.”
Original study: Jiang P, Gao Z, Zhao W, et al. Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention: a large single-center study. Chinese Medical Journal. 2019;132(8):914–921. doi.org/10.1097/CM9.0000000000000181
Was this helpful?
0 / 0